HK1058146A1 - Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders - Google Patents

Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Info

Publication number
HK1058146A1
HK1058146A1 HK04100882A HK04100882A HK1058146A1 HK 1058146 A1 HK1058146 A1 HK 1058146A1 HK 04100882 A HK04100882 A HK 04100882A HK 04100882 A HK04100882 A HK 04100882A HK 1058146 A1 HK1058146 A1 HK 1058146A1
Authority
HK
Hong Kong
Prior art keywords
neuropathic pain
formulations
compositions
pain disorders
inhibiting progression
Prior art date
Application number
HK04100882A
Other languages
English (en)
Inventor
Ramasharma Kristipati
Peter Isadore Adriaenssens
Stephen Scott Bowersox
Theresa Gadbois
Robert R Luther
Gary Arthur Amstutz
Mark Raymond Pettus
Kishochandra Gohil
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/496,847 external-priority patent/US5795864A/en
Priority claimed from US08/613,400 external-priority patent/US6054429A/en
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of HK1058146A1 publication Critical patent/HK1058146A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A61P23/02—Local anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Control Of El Displays (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
HK04100882A 1995-06-27 2004-02-10 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders HK1058146A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/496,847 US5795864A (en) 1995-06-27 1995-06-27 Stable omega conopetide formulations
US08/613,400 US6054429A (en) 1996-03-08 1996-03-08 Epidural method of producing analgesia

Publications (1)

Publication Number Publication Date
HK1058146A1 true HK1058146A1 (en) 2004-05-07

Family

ID=27052304

Family Applications (1)

Application Number Title Priority Date Filing Date
HK04100882A HK1058146A1 (en) 1995-06-27 2004-02-10 Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders

Country Status (14)

Country Link
EP (2) EP0835126B1 (fr)
JP (1) JP2838073B2 (fr)
AT (2) ATE235914T1 (fr)
AU (1) AU695166B2 (fr)
CA (1) CA2224795C (fr)
DE (3) DE69637021T2 (fr)
DK (2) DK0835126T3 (fr)
ES (2) ES2283671T3 (fr)
FR (1) FR05C0027I2 (fr)
HK (1) HK1058146A1 (fr)
LU (1) LU91181I2 (fr)
NL (1) NL300201I2 (fr)
PT (2) PT1336409E (fr)
WO (1) WO1997001351A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5931809A (en) * 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU6109698A (en) * 1998-02-20 1999-09-06 Zeneca Limited Analgesic peptides from venom of (grammostola spatulata) and use thereof
AUPP627498A0 (en) 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
EP2386566A3 (fr) 2002-12-02 2012-02-15 Xenome Ltd Peptides de chi-conotoxine (II)
US7851444B2 (en) 2002-12-02 2010-12-14 Xenome Ltd. χ-conotoxin peptides (-1)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
CN100589839C (zh) 2003-01-28 2010-02-17 艾恩伍德医药品股份有限公司 多肽及包含多肽的药物组合物
EP1689401A1 (fr) 2003-10-02 2006-08-16 Elan Pharmaceuticals, Inc. Methode de soulagement de la douleur
GB0410215D0 (en) * 2004-05-07 2004-06-09 Lescroart Pol Nerve damage
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
CN101557820A (zh) * 2006-11-04 2009-10-14 安奈根株式会社 ω芋螺毒素
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
US20110129508A1 (en) * 2008-05-06 2011-06-02 Relevare Aust. Pty Ltd Methods and compositions for the management of pain using omega-conotoxins
CA2930674A1 (fr) 2008-06-04 2009-12-10 Synergy Pharmaceuticals Inc. Agonistes de guanylate cyclase utile dans le traitement de troubles gastro-intestinaux, d'une inflammation, d'un cancer et d'autres troubles
JP2011528375A (ja) 2008-07-16 2011-11-17 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸障害、炎症、癌、およびその他の障害の治療のために有用なグアニル酸シクラーゼのアゴニスト
JP5964589B2 (ja) 2008-12-03 2016-08-03 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃアゴニストの製剤およびその使用方法
HUE036405T2 (hu) 2008-12-31 2018-07-30 Ardelyx Inc Vegyületek és módszerek az NHE-közvetített (Na+/H+ cserével mûködõ) antiport gátlására folyadékretencióval vagy túlzott sómennyiség jelenlétével és a gyomor-bél traktus zavaraival összefüggõ rendellenességek kezelésében
WO2018129556A1 (fr) 2017-01-09 2018-07-12 Ardelyx, Inc. Composés et procédés pour l'inhibition d'un antiport à médiation par échangeur sodium/proton (nhe) dans le traitement de troubles associés à une rétention d'eau ou à une surcharge en sel et de troubles du tractus gastro-intestinal
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2880338A1 (fr) 2012-08-21 2014-02-27 Ardelyx, Inc. Composes et procedes d'inhibition d'un antiport a mediation par nhe dans le traitement de troubles associes a une retention de fluide ou a une surcharge de sel et de troubles du tractus gastro-intestinal
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
CA2905438A1 (fr) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonistes de la guanylate cyclase et leurs utilisations
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
SI2983667T1 (sl) 2013-04-12 2019-09-30 Ardelyx, Inc. Spojine za vezavo NHE3 in metode za zaviranje transporta fosfata
JP6606491B2 (ja) 2013-06-05 2019-11-13 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼｃの超高純度アゴニスト、その作成および使用方法
US11147884B2 (en) 2017-01-09 2021-10-19 Ardelyx, Inc. Inhibitors of NHE-mediated antiport
EP3565808A1 (fr) 2017-01-09 2019-11-13 Ardelyx, Inc. Composés utiles pour le traitement de troubles du tractus digestif

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
AU3074592A (en) * 1991-11-12 1993-06-15 Neurex Corporation Compositions for delayed treatment of ischemia-related neuronal damage
ATE165977T1 (de) * 1991-12-30 1998-05-15 Neurex Corp Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
JPH06247879A (ja) * 1993-02-17 1994-09-06 Bristol Myers Squibb Co デオキシチミジンヌクレオシドを含有する注射用製剤の安定化方法およびその方法によって得られる安定化注射用製剤

Also Published As

Publication number Publication date
AU6400296A (en) 1997-01-30
NL300201I2 (nl) 2006-02-01
LU91181I2 (fr) 2005-09-06
DE122005000043I1 (de) 2006-06-29
WO1997001351A1 (fr) 1997-01-16
DK0835126T3 (da) 2003-07-14
NL300201I1 (nl) 2005-09-01
DE69637021D1 (de) 2007-05-24
ES2283671T3 (es) 2007-11-01
AU695166B2 (en) 1998-08-06
DE69627153D1 (de) 2003-05-08
ATE235914T1 (de) 2003-04-15
ES2194998T3 (es) 2003-12-01
PT1336409E (pt) 2007-06-29
FR05C0027I2 (fr) 2006-12-29
DE122005000043I2 (de) 2006-08-03
EP1336409A1 (fr) 2003-08-20
EP0835126B1 (fr) 2003-04-02
CA2224795A1 (fr) 1997-01-16
FR05C0027I1 (fr) 2005-08-12
JP2838073B2 (ja) 1998-12-16
DK1336409T3 (da) 2007-08-13
DE69627153T2 (de) 2003-12-04
JPH09104634A (ja) 1997-04-22
ATE359086T1 (de) 2007-05-15
CA2224795C (fr) 2001-04-03
DE69637021T2 (de) 2008-01-10
EP1336409B1 (fr) 2007-04-11
EP0835126A1 (fr) 1998-04-15
PT835126E (pt) 2003-07-31

Similar Documents

Publication Publication Date Title
HK1058146A1 (en) Compositions and formulations for producing analgesia and for inhibiting progression of neuropathic pain disorders
IL121170A0 (en) Compositions for the treatment of dermatological disorders
BG101901A (en) 2-methyl-thieno-benzodiazepine formulation for oral application
HK1008180A1 (en) Use of vitamin d 2 or vitamin d 4-derivatives for the manufacture of a medicament for the treatment of secondary hyperparathyroidism
EP0788359A4 (fr) Compositions utiles a la preparation de medicaments destines au traitement de divers troubles refractaires
IL112029A (en) Raloxifine and related compounds for use as medicaments for the treatment of disorders associated with an excess of tachykinin
AU7397094A (en) Prevention and treatment of alzheimer's disease
SG46737A1 (en) Oral formulations of s(+) - etodolac
CA2279498A1 (fr) Utilisation de la levobupivacaine en chirurgie infantile
IL134263A0 (en) Use of phanquinone for the treatment of alzheimer's disease
CA2135709A1 (fr) Derives de melatonine servant au traitement des troubles du sommeil
AU3358295A (en) A device for the manufacture of dental fillings and the like
GB9303157D0 (en) Treatment of a group of related disorders
GB9518887D0 (en) Treatment of muscular disorders
UA29461C2 (uk) Засіб для лікування амілоїдозу, спосіб лікування амілоїдозу
AU6678194A (en) Agents for the prevention and treatment of huntington's disease and other neurological disorders
AU1807592A (en) New combination preparation for treatment of parkinson's disease
ZA947912B (en) Treatment of medical disorders associated with free radical formation
CA2221592A1 (fr) Utilisation de forskoline ou d'extraits contenant cette substance dans la fabrication d'un medicament destine au traitement de l'alcoolisme
GR3034688T3 (en) Use of 6,7-substituted-2-aminotetralines for preparing pharmaceutical compositions useful for the treatment of septic shock, and antipyretic and antiinflammatory pharmaceutical compositions
AU124671S (en) Elongate frame extension
IL106917A0 (en) Compositions for the treatment of skin disorders
AU7340894A (en) Treatment of oral ailments
SI0836472T1 (en) Therapeutic effervescent compositions
GB9400970D0 (en) Manufacture of an oral solid dose form of lactitol

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130626